Trump and Xi Jinping May Have a Call Amid 'Stalled' Talks: Scott Bessent
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Treasury Secretary Scott Bessent said Thursday that trade talks with China are "a bit stalled," and that President Donald Trump and Chinese leader Xi Jinping may need to speak soon.
Speaking on Fox News' Special Report with Bret Baier, Bessent said in part, "I think that given the magnitude of the talks, given the complexity, this is going to require both leaders to weigh in with each other. They have a very good relationship, and I am confident the Chinese will come to the table when President Trump makes his preferences known."
JUST IN: 🇺🇸🇨🇳 Treasury Secretary Bessent says trade talks with China have "stalled." pic.twitter.com/AP9nl4OUew — Watcher.Guru (@WatcherGuru) May 29, 2025
This is developing news and will be updated as more information is available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
23 minutes ago
- Fox News
Trump's 20th week in office to include White House meeting with European leader, expected call with Xi
President Donald Trump's 20th week in the Oval Office is expected to include a White House meeting with Germany's chancellor, a phone call with Chinese President Xi Jinping and lawmakers' ongoing efforts to pass the "big, beautiful bill" to fund the president's agenda. Monday marks Trump's 134th day in the White House, a period in which he has issued 150 executive orders affecting domestic policies, unveiled sweeping plans to rectify the nation's trade deficit with foreign nations and held ongoing negotiations to end international wars. The week is slated to include a meeting with German Chancellor Friedrich Merz at the White House as war continues to rage between Ukraine and Russia and trade negotiations with the U.S. hang over Germany. Merz's office confirmed on Saturday that the chancellor will travel to Washington on Wednesday evening ahead of meeting Trump on Thursday, Politico reported. The two are slated to discuss the ongoing war between Russia and Ukraine and trade policies. Ukrainian President Volodymyr Zelenskyy met with Merz in Germany last week as the two European leaders ironed out an agreement for Germany to bolster its backing of Ukraine. The meeting on Thursday will be followed by a lunch and press conference, according to Bloomberg. Merz and Trump have previously spoken by phone but have not met face-to-face since Merz was elected Germany's leader in May. Merz clashed with Trump officials last month when Germany designated its right-wing Alternative for Germany political party a "proven right-wing extremist organization." "Germany just gave its spy agency new powers to surveil the opposition. That's not democracy–it's tyranny in disguise," Secretary of State Marco Rubio posted to X of the designation. "What is truly extremist is not the popular AfD–which took second in the recent election – but rather the establishment's deadly open border immigration policies that the AfD opposes." "Banning the centrist AfD, Germany's most popular party, would be an extreme attack on democracy," former Department of Government Efficiency chief Elon Musk posted to X, the social media platform that he owns. Merz responded that American leaders should not weigh in on German elections and politics. "We have largely stayed out of the American election campaign in recent years, and that includes me personally," Merz said, according to Politico. "We have not taken sides with either candidate. And I ask you to accept that in return," he added. Trump is expected to hold a phone call with China's Xi Jinping this week to discuss tariffs, White House National Economic Council Director Kevin Hassett revealed on Sunday. "President Trump, we expect, is going to have a wonderful conversation about the trade negotiations this week with President Xi. That's our expectation," Hassett said Sunday during an interview on ABC News' "This Week." A day for the phone call has not yet been locked down, according to Hassett. "You never know in international relations, but my expectation is that both sides have expressed a willingness to talk," Hassett said. "And I'd like to also add that people are talking every day, so [U.S. Trade Representative] Jamieson Greer, his team and President Xi's team in China, they're talking every day trying to move the ball forward on this matter." The Trump administration leveled tariffs as high as 145% on Chinese goods following the president's reciprocal tariff plans in April, when China retaliated against the U.S. with tariffs of their own. China and the U.S. reached a preliminary trade agreement last month, which Trump said China violated in a Truth Social post on Friday. "I made a FAST DEAL with China in order to save them from what I thought was going to be a very bad situation, and I didn't want to see that happen. Because of this deal, everything quickly stabilized and China got back to business as usual. Everybody was happy! That is the good news!!! The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US. So much for being Mr. NICE GUY!" he wrote. Senate lawmakers are working to pass the One Big Beautiful Bill Act, which is a multitrillion-dollar piece of legislation that advances Trump's agenda on taxes, immigration, energy, defense and the national debt. House lawmakers passed the legislation last month by one vote after a handful of Republican lawmakers held out on supporting the legislation, saying it would exacerbate the nation's debt. A handful of Republican senators have made similar remarks to their House counterparts, explaining they cannot support the legislation unless it addresses its impact on the nation's debt. The bill is expected to add roughly $3 trillion to the national debt, Fox News Digital previously reported. "I'm a 'no' unless we separate out the debt ceiling," Republican Kentucky Sen. Rand Paul said last week. "If you take the debt ceiling off the bill, I'm pretty much a 'yes' on most of the rest." "If we follow the path of the House bill, we'll have close to, I think, $60 trillion worth of debt in 10 years. What we've got to do is do what every family does: We've got to go through every line of the budget," Republican Sen. Rick Scott of Florida said during an interview on Fox News on Thursday. Republican South Dakota Sen. Mike Rounds told Fox News Digital in an exclusive interview from the Ronald Reagan Presidential Library in California on Friday that the Senate must pass the legislation or American families will pay higher taxes. "We don't have a choice. We have to pass the bill to get the Tax Cuts and Jobs Act back in place on a permanent basis," he said. "If we don't do that, the average American family is going to see about a $2,400-a-year increase in their taxes. So we have to do something. And it's critical that we pass this bill. We're going to work with the House. We're going to get this deal done. The Senate will put their mark of approval on it, but nonetheless, we want to do everything we can as quickly as we can to take care of this so that we can get on to other things. The president has made it very clear he wants to get this done. We want to help in that regard. This is our job." Trump has repeatedly called on lawmakers to unify and pass the legislation, saying that it is "arguably the most significant piece of legislation that will ever be signed in the history of our country."
UPI
32 minutes ago
- UPI
Hegseth: U.S. won't be 'pushed out' of Indo-Pacific 'priority theater'
Defense Secretary Pete Hegseth says nations must prepare for war to ensure peace amid Chinese aggression in the Indo-Pacific region during the International Institute for Strategic Studies Shangri-la Dialogue Defence Summit in Singapore on Saturday. Photo by How Hwee Young/EPA-EFE May 31 (UPI) -- The United States and its allies won't allow China to dominate the Indo-Pacific region, but do not seek war, Defense Secretary Pete Hegseth said Saturday morning in Singapore. He addressed regional concerns while speaking during the International Institute for Strategic Studies Shangri-La Dialogue event in Singapore. Hegseth said the Indo-Pacific region is the United States' "priority theater" and won't allow China to push the United States and its allies out of the region, the Department of Defense announced Friday in a news release. Instead, deterrence will be the primary tool by which the United States and its allies will counter any aggressive moves made by China, particularly in the South China Sea and against Taiwan. "As our allies share the burden, we can increase our focus on the Indo-Pacific," Hegseth said, adding that the region is the nation's "priority theater." He said the futures of the United States and its allies in the Indo-Pacific depend on each other. "We share a vision of peace and stability, of prosperity and security," Hegseth said, "and we are here to stay." Common sense and national interests with guide policy making in the region, while respecting mutual self-interests. President Donald Trump is working to get European nations to do more to increase their respective national security interests instead of largely relying on the United States. As European nations do more to protect themselves, Hegseth said the United States will be better able to focus on matters in the Indo-Pacific region and do more to thwart Chinese aggression. "This enables all of us to benefit from the peace and stability that comes with a lasting and strong American presence here in the Indo-Pacific," Hegseth said. That presence won't come at a cost for the nation's allies, though. "We are not here to pressure other countries to embrace and adopt our politics or ideology," Hegseth told the audience. "We are all sovereign nations." He said the United States does not "seek conflict with communist China." But the United States "will not be pushed out of this critical region," Hegseth added. "And we will not let our allies and partners be subordinated and intimidated." He said China's leaders are "preparing to use military force to alter the balance of power in the Indo-Pacific," including occupying Taiwan. Any move by China to take over Taiwan, which China has claimed as part of its sovereign state, would trigger "devastating consequences" for the region and the world, Hegseth told the audience. "The threat China poses is real, and it could be imminent," he said, adding that the United States and its allies must be prepared with "urgency and vigilance." If deterrence doesn't work and a fighting war is inevitable, "we are prepared to do what the Department of Defense does best: to fight and win decisively," Hegseth said. The best way to ensure peace is to prepare for war, "but we have to do this quickly," he said. "We have no time to waste."
Yahoo
33 minutes ago
- Yahoo
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Summit Therapeutics stock fell hard recently in response to disappointing clinical trial results. Ivonescimab failed to produced a statistically significant overall survival benefit in the phase 3 Harmoni trial. Ivonescimab has been approved by Chinese regulators, but Summit Therapeutics has a license to sell it outside of China. 10 stocks we like better than Summit Therapeutics › Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down. Stock markets have a tendency to sell first and ask questions later. After watching this stock plummet, some bargain-shoppers are wondering if it fell too far. Recent trial results missed the mark the company was hoping for, but the results weren't entirely discouraging. Let's weigh the bad news against the good to see if this stock could be a beaten-down bargain. Summit Therapeutics and its investors have been eagerly anticipating results from the phase 3 Harmoni trial of ivonescimab. It's a bispecific antibody that works like a compination of Keytruda (a PD-1 inhibitor) plus Avastin (a VEGF inhibitor). Summit's stock price rocketed higher in 2024 thanks to Harmoni-2 trial results that showed it outperformed Keytruda at limiting tumor growth in lung cancer patients. Although ivonescimab is already approved in China, it's not for sale in the U.S. and EU, where Summit Therapeutics has a license to sell it. The Harmoni trial enrolled second-line lung cancer patients and treated them with ivonescimab or a placebo plus standard chemo. The treatment reduced the risk of disease progression in terms of tumor growth by 48%, but failed to show a convincing overall survival benefit. Adding ivonescimab to standard chemo reduced patients' risk of death by 21%, but the results fell just outside a 95% confidence interval with a p-value of 0.057. It's highly unlikely the Food and Drug Administration will approve ivonescimab for sale in the U.S. based on the Harmoni trial results. According to Summit, the FDA has been clear about the need for a statistically significant overall survival benefit to support an application. The China-based company that owns ivonescimab, Akeso, recently earned a second approval to market the therapy to lung cancer patients in China. Keytruda sales rose to $29.5 billion last year, and a treatment that can outperform the leader could do even better. Ivonescimab is unlikely to earn approval in the U.S. for patients similar to those enrolled in the Harmoni trial. Given its ability to shrink tumors, though, it's probably just a matter of time before it produces statistically significant overall survival results for an underserved patient population. Tumor responses get attention, but oncologists are far more interested in giving patients a chance for long-term survival. Keytruda's a top seller now because it produced dramatic overall survival results, compared to the standard treatments of its time. The lack of convincing overall survival data so far for ivonescimab severely reduces the odds that it will go on to produce blockbuster sales in the places where Summit Therapeutics has a license to sell it. Despite the obvious challenges ahead, expectations are still sky-high. Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is the only candidate in its pipeline. Despite the lack of options and an uncertain path forward, the stock finished May with a market cap above $13.5 billion. If ivonescimab goes on to produce sales anywhere near Keytruda's, investors who bought Summit Therapeutics at recent prices could reap enormous gains. Unfortunately, the Harmoni trial's failure to produce a convincing overall survival benefit suggests that future sales will be muted, even if the company can get it past the FDA. It's probably best to watch this story play out from a safe distance. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? was originally published by The Motley Fool Sign in to access your portfolio
